To empower patients to lead healthier lives by harnessing the power of red blood cells to deliver precision medicine for better lipid management.
By 2030, more than 65% of US population is estimated to be adults with cardiovascular burden requiring healthcare expenses of over $800 billion. Annual expenses for one high-risk ASCVD patient is expected to be $50,000.
Our addressable market is greater than two million high-risk ASCVD patients in the US.
We have a small molecule agent with a unique combination of mechanisms to provide for a robust decrease in plasma LDL-C and Lp(a). Our red cell delivery technology is intended to provide for a long duration of action (monthly or less frequent) in high-risk ASCVD patients on maximally tolerated lipid lowering therapies.
Copyright © 2020 Ayma Therapeutics Inc. - All Rights Reserved.